A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Description

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus. The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus. Patients will be assigned to receive either AB-101 alone as mon

Trial Eligibility

Inclusion Criteria for Lupus Nephritis: * Adult subjects with biopsy proven lupus nephritis Class III or IV either with or without the presence of Class V according to the 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria, who failed or did not respond to previous standard of care treatment approaches * A kidney biopsy must be performed \< 24 weeks prior to the screening visit or during the screening period. * Eligible subjects must have evidence of active disease on renal biopsy based on the modified NIH Lupus Nephritis activity and chronicity indices. * Eligible subjects must have detectable anti-double stranded DNA antibody titers for enrollment. Inclusion Criteria for Refractory Systemic Lupus Erythematosus: * Diagnosis of SLE according to the 2019 EULAR/ACR Classification Criteria * Total SLE Disease Activity Index (SELENA-SLEDAI score) \>8 sat screening * Failed at least 12 weeks of 2 conventional therapies for SLE Exclusion Criteria: * Known past or current malignancy other than protocol stipulated low grade cancers, or curable cancer in complete response for \>2 years * Known clinically significant cardiac disease * Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE * Subjects with known active viral infections or, if with a history of HBV or HCV infections, have a viral load above the institution's limit of quantitation

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.